Biomarin Pharmaceutical BMRN reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Biomarin Pharmaceutical missed estimated earnings by 300.0%, reporting an EPS of $-0.04 versus an estimate of $-0.01.
Revenue was up $96.60 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.48 which was followed by a 5.18% increase in the share price the next day.
Here's a look at Biomarin Pharmaceutical's past performance:
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.11 | -0.32 | -0.25 | |
| EPS Actual | 0.59 | 0.17 | -0.32 | -0.20 |
| Revenue Estimate | 521.47M | 507.52M | 442.39M | 435.32M |
| Revenue Actual | 533.80M | 519.36M | 449.81M | 408.74M |
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.11 | -0.32 | -0.25 | |
| EPS Actual | 0.59 | 0.17 | -0.32 | -0.20 |
| Revenue Estimate | 521.47M | 507.52M | 442.39M | 435.32M |
| Revenue Actual | 533.80M | 519.36M | 449.81M | 408.74M |
To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.